NasdaqGS:TLRY

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Market Cap

US$5.7b

Last Updated

2021/07/28 03:00 UTC

Data Sources

Company Financials +

Executive Summary

Tilray Inc. engages in the research, cultivation, production, and distribution of medical cannabis and cannabinoids. More Details


Snowflake Analysis

High growth potential and slightly overvalued.


Similar Companies

Share Price & News

How has Tilray's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: TLRY is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 11% a week.

Volatility Over Time: Insufficient data to determine TLRY's volatility change over the past year.


Market Performance


7 Day Return

-10.1%

TLRY

2.0%

US Pharmaceuticals

0.9%

US Market


1 Year Return

n/a

TLRY

16.2%

US Pharmaceuticals

37.8%

US Market

Return vs Industry: Insufficient data to determine how TLRY performed against the US Pharmaceuticals industry.

Return vs Market: Insufficient data to determine how TLRY performed against the US Market.


Shareholder returns

TLRYIndustryMarket
7 Day-10.1%2.0%0.9%
30 Day-30.1%3.2%0.3%
90 Dayn/a8.2%2.1%
1 Yearn/a21.1%16.2%40.0%37.8%
3 Yearn/a32.7%21.5%63.8%53.5%
5 Yearn/a47.4%28.4%124.6%99.7%

Long-Term Price Volatility Vs. Market

How volatile is Tilray's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Tilray undervalued compared to its fair value and its price relative to the market?

38.5%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: TLRY ($12.73) is trading below our estimate of fair value ($20.69)

Significantly Below Fair Value: TLRY is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: TLRY is unprofitable, so we can't compare its PE Ratio to the US Pharmaceuticals industry average.

PE vs Market: TLRY is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate TLRY's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: TLRY is overvalued based on its PB Ratio (3.4x) compared to the US Pharmaceuticals industry average (2.9x).


Future Growth

How is Tilray forecast to perform in the next 1 to 3 years based on estimates from 7 analysts?

73.3%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: TLRY is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2%).

Earnings vs Market: TLRY is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: TLRY's is expected to become profitable in the next 3 years.

Revenue vs Market: TLRY's revenue (22.7% per year) is forecast to grow faster than the US market (9.2% per year).

High Growth Revenue: TLRY's revenue (22.7% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: TLRY's Return on Equity is forecast to be low in 3 years time (9.2%).


Past Performance

How has Tilray performed over the past 5 years?

-76.2%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: TLRY is currently unprofitable.

Growing Profit Margin: TLRY is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: TLRY is unprofitable, and losses have increased over the past 5 years at a rate of 76.2% per year.

Accelerating Growth: Unable to compare TLRY's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: TLRY is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (10.1%).


Return on Equity

High ROE: TLRY has a negative Return on Equity (-37.38%), as it is currently unprofitable.


Financial Health

How is Tilray's financial position?


Financial Position Analysis

Short Term Liabilities: TLRY's short term assets (CA$730.7M) exceed its short term liabilities (CA$217.0M).

Long Term Liabilities: TLRY's short term assets (CA$730.7M) do not cover its long term liabilities (CA$1.0B).


Debt to Equity History and Analysis

Debt Level: TLRY's debt to equity ratio (56.3%) is considered high.

Reducing Debt: Insufficient data to determine if TLRY's debt to equity ratio has reduced over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: TLRY has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if TLRY has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Dividend

What is Tilray current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate TLRY's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate TLRY's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if TLRY's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if TLRY's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of TLRY's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.9yrs

Average management tenure


CEO

Irwin Simon (63 yo)

2.33yrs

Tenure

CA$18,623,184

Compensation

Mr. Irwin David Simon has been Chairman of the Board of Tilray, Inc. since December 27, 2018, Chief Executive Officer since March 1, 2019 and President since May 4, 20201. Mr. Simon has been Executive Chai...


CEO Compensation Analysis

Compensation vs Market: Irwin's total compensation ($USD14.82M) is above average for companies of similar size in the US market ($USD6.51M).

Compensation vs Earnings: Irwin's compensation has increased whilst the company is unprofitable.


Leadership Team

Experienced Management: TLRY's management team is not considered experienced ( 1.9 years average tenure), which suggests a new team.


Board Members

Experienced Board: TLRY's board of directors are not considered experienced ( 1.6 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: TLRY insiders have only sold shares in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 56%.


Top Shareholders

Company Information

Tilray, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Tilray, Inc.
  • Ticker: TLRY
  • Exchange: NasdaqGS
  • Founded: NaN
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$5.718b
  • Shares outstanding: 449.17m
  • Website: https://www.tilray.com

Number of Employees


Location

  • Tilray, Inc.
  • 98 Talbot Street West
  • Leamington
  • Ontario
  • N8H 1M8
  • Canada

Listings


Biography

Tilray Inc. engages in the research, cultivation, production, and distribution of medical cannabis and cannabinoids. The company offers cannabis-lifestyle and consumer packaged goods; and hemp-based foods ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/07/28 03:00
End of Day Share Price2021/07/27 00:00
Earnings2021/02/28
Annual Earnings2020/05/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.